Global Bile Duct Cancer Market to Garner Reach US$ 312 Mn by 2025 end

Cholangiocarcinoma, also known as bile duct cancer, is spreading widely in Southeast Asia, particularly in the Northeast region of Thailand. High consumption of raw fish in the Asia-Pacific (APAC) region is driving the incidence of liver fluke infections, thereby stimulating the occurrence of bile duct cancer. Increased industrialization is also attributing to the growth in the APAC bile duct cancer treatment market as exposure to harmful printing chemicals is high among industrial workers in countries such as China, Japan and India. Persistence Market Research’s new study on the global bile duct cancer treatment market reveals that by the end of 2025, APAC region will procure a global revenue share of over 45%.

In 2017, the global market for bile duct cancer treatments is anticipated to bring in revenues worth a little over US$ 168 Mn. Apart from rising incidence of bile duct cancer across the APAC and Middle East & Africa region, increasing healthcare spending is also expected to drive the demand for bile duct cancer treatments. Towards the end of 2025, the global bile duct cancer treatment market is projected to soar at a robust CAGR of 8%, raking in revenues worth US$ 312.3 Mn.

Download Report Table of Content, Figures, and Tables @ http://www.persistencemarketresearch.com/market-research/bile-duct-cancer-treatment-market/toc

Bile Duct Cancer Treatment – Key Challenges

The study has observed following factors as key hurdles hindering the overall expansion of global Cholangiocarcinoma treatment market:

• high costs of cancer treatment in the US

• lack of awareness on causes of Cholangiocarcinoma in developing regions

• regulatory agencies rebuffing approval of expensive drugs

• unavailability of effective cancer care in APAC region

• poor diagnosis rate and absence of clinical data

The study also reveals that ongoing trials for development of drugs on bile duct cancer treatment are creating newer pathways for improving the efficiency of treatment. Companies are exploring the clinical benefits of fusing new chemical entities in existing drugs on treatment of bile duct cancer. The key players in global bile duct cancer treatment market are also seeking regulatory approval of combination therapies for treatment of Cholangiocarcinoma. The study has recorded such developments while profiling the market’s leading participants, which include Pfizer, Inc., F. Hoffman-La Roche AG, Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Eli Lilly and Company, Novartis AG, Sanofi, Fresenius Kabi AG, Mylan N.V., Kyowa Hakko Kirin Co Ltd., Intercept Pharmaceuticals, Inc., Accord Healthcare Inc., Delcath Systems Inc., Celgene Corporation, and Johnson & Johnson.

A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/10094

Key Excerpts from the Study

Treatment of bile duct cancer is presently achieved through combination therapies associated with chemotherapy. The study anticipates that by the end of forecast period, close to 70% of global bile duct cancer treatment revenues will be accounted by the Gemicitabine Combination Therapy.

In 2017 and beyond, more than 85% of global market value will be attributed by extrahepatic Cholangiocarcinoma as a disease indicator.

The study also observes hospital pharmacies as largest distribution channel for bile duct cancer drugs, revenues from which are expected to reach nearly US$ 250 Mn by 2025-end.

The global market for Cholangiocarcinoma treatment is also witnessing dominance from external beam radiation therapy as these services are pegged to procure more than half of market’s value through 2025.

Browse Complete Report @ http://www.persistencemarketresearch.com/market-research/bile-duct-cancer-treatment-market.asp

About Us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our offerings include pre-built reports that address every major sale, customized solutions to cater to client-specific needs, and consulting services to offer more value addition. Our next-generation research approach for exploring emerging technologies has allowed us to solve the most complex problems of clients. We do not follow a reactive approach, but a pro-active one. Expert analysts at PMR keep a tab on next-generation technologies in their R&D phase and provide the latest insights into these technologies when they are being commercialized. Our ground-breaking approach allows us to deliver market solutions before the technologies reach the market.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact

Persistence Market Research Pvt. Ltd

305 Broadway

7th Floor, New York City,

NY 10007, United States,

USA – Canada Toll Free: 800-961-0353

Email: sales@persistencemarketresearch.com

media@persistencemarketresearch.com

Persistence Market Research (Pmr) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.